Neuren Pharmaceuticals Limited (ASX:NEU)

Market Cap	1.56B +42.4%
Revenue (ttm)	64.65M -70.2%
Net Income	30.44M -78.6%
EPS	0.23 -78.6%
Shares Out	126.45M
PE Ratio	52.99
Forward PE	96.46
Dividend	n/a
Ex-Dividend Date	n/a

Volume	275,914
Average Volume	312,212
Open	12.15
Previous Close	12.18
Day's Range	12.01 - 12.33
52-Week Range	10.92 - 22.99
Beta	1.58
RSI	49.42
Earnings Date	May 29, 2026

About Neuren Pharmaceuticals

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develo...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 8
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: NEU

Financial Performance

In 2025, Neuren Pharmaceuticals's revenue was 64.65 million, a decrease of -70.18% compared to the previous year's 216.83 million. Earnings were 30.44 million, a decrease of -78.57%.